Neurocrine Biosciences (NBIX) Misses Q1 EPS by 7c
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $168.52 --0%
EPS Growth %: -4.2%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
DTGI, OCCI, MAYS, More
EPS Growth %: -4.2%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
DTGI, OCCI, MAYS, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of $0.70, $0.07 worse than the analyst estimate of $0.77. Revenue for the quarter came in at $572.6 million versus the consensus estimate of $593.71 million.
GUIDANCE
INGREZZA Net Product Sales between $2.5-2.6 billion
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Carlisle Made Unsolicited Offers for Rival Owens Corning - WSJ
- Viridian Therapeutic (VRDN) PT Raised to $43 at Wedbush
- Retrieve Medical signs distribution deal with podiatry network
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
